Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023 in Two Oral Presentations and Two Poster Presentations
Additionally, we will be presenting the first AUTO8 clinical data from the MCARTY Phase I study in multiple myeloma.”
- Additionally, we will be presenting the first AUTO8 clinical data from the MCARTY Phase I study in multiple myeloma.”
Session Title: 704. - In this session, pooled analysis of data from all patients treated to date in the FELIX study will be presented, with an extended follow up.
- In the MCARTY study, we demonstrate dual CD19/BCMA targeting, alongside feasibility of clinical grade manufacture by double-transduction.
- Additionally, obe-cel has been tested in patients with R/R B-cell chronic lymphocytic leukemia (B-CLL) and R/R B-cell non-Hodgkin lymphoma (B-NHL).